Cost-effectiveness of emicizumab for the treatment of hemophilia A: a systematic review

BackgroundEmicizumab, a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis of bleeding episodes in people with hemophilia A, can impose a significant financial burden. We conducted a systematic review to evaluate the reporting quality of existing pharmacoeconomic...

Full description

Bibliographic Details

Published in:	Frontiers in Public Health
Main Authors:	Min Chen, Yunzhu Lin, Guoqian He, Liang Huang, Junyi Han, Jiaqi Ni
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-10-01
Subjects:	hemophilia A emicizumab cost-effectiveness systematic review pharmacoeconomic
Online Access:	https://www.frontiersin.org/articles/10.3389/fpubh.2025.1658760/full